Galleri

Galleri is a multi-cancer early detection test that uses a single blood draw to screen for over 50 types of cancer. It is recommended for adults aged 50 or older who are at an elevated risk for cancer. Galleri is not a diagnostic test and does not detect all cancers. A positive result requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable. GRAIL's Galleri® test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Accuray Incorporated is a radiation oncology company that develops, manufactures, and sells radiation therapy systems and software for the treatment of cancer. Accuray's products are used by radiation oncologists to deliver precise and effective radiation therapy treatments to patients with a variety of cancers, including prostate cancer, breast cancer, lung cancer, and brain cancer. Accuray's mission is to expand the curative power of radiation therapy to improve as many lives as possible.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover valuable insights. The platform is purpose-built for various conditions such as cancer, immune, endocrine, metabolic system, chronic diseases, aging, infectious diseases, and mental health, offering solutions for early biomarker discovery, drug repurposing, lead identification, compound optimization, trial monitoring, and response to treatment. JADBio is trusted by partners in precision health & medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.

Viz.ai is an AI-powered care coordination platform that helps providers improve patient outcomes. The platform uses advanced algorithms to analyze medical imaging data and provide real-time insights and automated assessments to accelerate diagnosis and treatment. Viz.ai's solutions are used by hospitals and health systems across the country to improve care for patients with a variety of conditions, including stroke, heart disease, and cancer.

Viz.ai is a leading provider of AI-powered care coordination solutions for healthcare providers. Its comprehensive platform leverages advanced algorithms to analyze medical imaging data, providing real-time insights and automated assessments to accelerate diagnosis and treatment. Viz.ai's solutions cover a wide range of therapeutic areas, including neurology, cardiology, vascular medicine, trauma, and radiology. The company's mission is to improve patient outcomes by closing the gaps between patients, clinicians, and life-saving treatments.

PMcardio is an AI-powered ECG interpretation platform that offers accurate diagnosis of cardiovascular diseases within seconds. It provides rapid referral to specialists, detects occlusion myocardial infarction, and identifies reduced left ventricular ejection fraction from 12-lead ECGs. PMcardio enhances clinical decision-making, standardizes ECG reports, and ensures data security. The platform is designed for both individuals and organizations in the healthcare sector, offering seamless coordination and high accuracy in diagnostics.

Beacon Biosignals provides an EEG neurobiomarker platform that is designed to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric diseases. Their platform is powered by machine learning and a world-class clinico-EEG database, which allows them to analyze existing EEG data for insights into mechanisms, PK/PD, and patient stratification. This information can be used to guide further development efforts, optimize clinical trials, and enhance understanding of treatment efficacy.

Butterfly iQ3 is a handheld, whole-body ultrasound device that provides clear and detailed images for a variety of medical applications. It is the third-generation probe from Butterfly Network, and it features double the processing power and clearer images than its predecessors. Butterfly iQ3 is also equipped with real-time AI, which can help clinicians to identify and diagnose medical conditions more quickly and accurately. The device is lightweight and portable, making it easy to use in a variety of settings, including the clinic, the hospital, and the field. Butterfly iQ3 is a valuable tool for clinicians who want to improve the quality of care they provide to their patients.

Cleerly is a digital healthcare company transforming the way clinicians approach the treatment of heart disease. Our clinically-proven, AI-based digital care platform works with coronary computed tomography angiography (CCTA) imaging to help clinicians precisely identify and define atherosclerosis earlier, so they can provide personalized, life-saving treatment plans for all patients throughout their care continuum. We measure atherosclerosis - plaque build-up in the heart's arteries - not indirect markers such as risk factors and symptoms of disease. Our AI-enabled digital care pathway offers simpler, faster, more accurate heart disease evaluation and reporting that's tailored to each stakeholder, improving overall clinical and financial outcomes.

NeuProScan is an AI platform designed for the early detection of pre-clinical Alzheimer's from MRI scans. It utilizes AI technology to predict the likelihood of developing Alzheimer's years in advance, helping doctors improve diagnosis accuracy and optimize the use of costly PET scans. The platform is fully customizable, user-friendly, and can be run on devices or in the cloud. NeuProScan aims to provide patients and healthcare systems with valuable insights for better planning and decision-making.

Linus Health is a next-generation digital cognitive assessment platform that enables earlier detection and intervention in brain health. It brings the power of AI to long-trusted cognitive tests, delivering rich insights and actionable clinical guidance. Linus Health's technology has been validated in over 20 published studies and is used by leading organizations to transform their approach to brain health.

Lunit Inc. is a leading provider of AI-powered cancer screening and treatment solutions. The company's mission is to conquer cancer through AI by developing innovative technologies that can help detect and treat cancer earlier and more effectively. Lunit's AI solutions are used by hospitals and clinics around the world to improve the accuracy and efficiency of cancer diagnosis and treatment.

Azyri is an AI-powered medical assistant that provides bone age assessment services to healthcare professionals, students, and AI enthusiasts. It offers free access to its AI-based bone age estimation tool, allowing users to obtain an estimate of a patient's bone age from a simple X-ray image. Azyri's mission is to make bone age assessment more accessible and efficient, empowering healthcare providers with valuable insights for patient care.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Galleri is a multi-cancer early detection test that uses a single blood draw to screen for over 50 types of cancer. It is recommended for adults aged 50 or older who are at an elevated risk for cancer. Galleri is not a diagnostic test and does not detect all cancers. A positive result requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable. GRAIL's Galleri® test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

iCAD is an AI-powered application designed for cancer detection, specifically focusing on breast cancer. The platform offers a suite of solutions including Detection, Density Assessment, and Risk Evaluation, all backed by science, clinical evidence, and proven patient outcomes. iCAD's AI-powered solutions aim to expose the hiding place of cancer, providing certainty and peace of mind, ultimately improving patient outcomes and saving more lives.

Caption Care provides accessible cardiac ultrasounds to detect heart disease earlier, when it's easier and more cost-effective to manage. The result: better patient outcomes, more accurate risk scoring, and reduced downstream costs.

Lunit Inc. is a leading provider of AI-powered cancer screening and treatment solutions. The company's mission is to conquer cancer through AI by developing innovative technologies that can help detect and treat cancer earlier and more effectively. Lunit's AI solutions are used by hospitals and clinics around the world to improve the accuracy and efficiency of cancer diagnosis and treatment.

Galleri is a multi-cancer early detection test that uses a single blood draw to screen for over 50 types of cancer. It is recommended for adults aged 50 or older who are at an elevated risk for cancer. Galleri is not a diagnostic test and does not detect all cancers. A positive result requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

The National Cancer Institute's Center for Biomedical Informatics and Information Technology (CBIIT) provides a comprehensive suite of tools, resources, and training to support cancer data science research. These resources include data repositories, analytical tools, data standards, and training materials. CBIIT also develops and maintains the NCI Thesaurus, a comprehensive vocabulary of cancer-related terms, and the Cancer Data Standards Registry and Repository (caDSR), a repository of cancer data standards. CBIIT's mission is to accelerate the pace of cancer research by providing researchers with the tools and resources they need to access, analyze, and share cancer data.

FutureKid.ai is an AI-powered application that allows users to generate pictures of their future kids using just one image of each parent. The application uses advanced AI algorithms to create realistic HD images that provide a glimpse into the user's future family. The process is automated, ensuring user privacy by deleting all data from servers within 24 hours. FutureKid.ai is a German-based company that values user privacy and offers a unique way to visualize potential future offspring.

GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable. GRAIL's Galleri® test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

SeeYourBabyAI is an AI-powered platform that offers a unique service to predict the appearance of your future baby based on photos of you and your partner. By leveraging advanced AI technology, the platform generates realistic images of potential sons and daughters with a high level of accuracy. Users can upload their photos, receive multiple AI-generated baby photos, and share them with family and friends. The platform focuses on precision, respects ethnic backgrounds, ensures privacy through encryption, and provides high-resolution, realistic photos for a one-time payment. SeeYourBabyAI aims to provide users with a heartwarming and fun experience of visualizing their future children.

Protocol Pal is a website designed to help users with building protocols. It is a user-friendly platform created by Basam Alasaly, Oceanexplains, and Tkruer. The website aims to simplify the process of creating protocols for various purposes. Users can easily navigate through the platform to generate structured protocols efficiently. Protocol Pal is a valuable tool for researchers, scientists, and professionals who require well-defined protocols for their work.

Proscia is a leading provider of digital pathology solutions for the modern laboratory. Its flagship product, Concentriq, is an enterprise pathology platform that enables anatomic pathology laboratories to achieve 100% digitization and deliver faster, more precise results. Proscia also offers a range of AI applications that can be used to automate tasks, improve diagnostic accuracy, and accelerate research. The company's mission is to perfect cancer diagnosis with intelligent software that changes the way the world practices pathology.

Oncora Medical is a healthcare technology company that provides software and data solutions to oncologists and cancer centers. Their products are designed to improve patient care, reduce clinician burnout, and accelerate clinical discoveries. Oncora's flagship product, Oncora Patient Care, is a modern, intelligent user interface for oncologists that simplifies workflow, reduces documentation burden, and optimizes treatment decision making. Oncora Analytics is an adaptive visual and backend software platform for regulatory-grade real world data analytics. Oncora Registry is a platform to capture and report quality data, treatment data, and outcomes data in the oncology space.

Owkin is a full-stack AI biotech company that integrates the best of human and artificial intelligence to deliver better drugs and diagnostics at scale. By understanding complex biology through AI, Owkin identifies new treatments, de-risks and accelerates clinical trials, and builds diagnostic tools to reduce time to impact for patients.

BetterMedicine is an AI software designed for cancer diagnostics and detection. It offers AI-powered solutions to enhance patient outcomes and drive efficiency in radiology workflows. The software is expertly designed by medical professionals and AI specialists, providing trusted and clinically validated solutions. BetterMedicine aims to address inefficiencies in radiology by integrating AI-powered software for detecting lesions on CT scans seamlessly into the workflow, thereby improving efficiency and reducing the risk of oversight. The application focuses on improving patient outcomes, reducing errors, and enhancing the wellbeing of radiology professionals.

iCAD is an AI-powered application designed for cancer detection, specifically focusing on breast cancer. The platform offers a suite of solutions including Detection, Density Assessment, and Risk Evaluation, all backed by science, clinical evidence, and proven patient outcomes. iCAD's AI-powered solutions aim to expose the hiding place of cancer, providing certainty and peace of mind, ultimately improving patient outcomes and saving more lives.

MediNav is an AI-powered medical assistant that learns and reduces documentation time for healthcare professionals. It is not just a medical dictation software but an assistant based on a complex algorithm that retains, notes, extracts medical information, and continuously learns. It helps in reducing costs by minimizing the need for additional staff during consultations or transcription, allowing more time for patients to be served, and ensuring faster delivery of imaging results to satisfied clients. MediNav is designed for various medical specialties such as Radiology, Cardiology, Gastroenterology, Pathology, and more. It uses cutting-edge speech recognition technology combined with natural language processing to achieve high accuracy. The assistant improves by learning from corrections made to its output, is robust to mild and moderate accents, and adapts quickly to new specialties. It also employs federated learning to share improvements securely across clinics without moving data.

LifeSciencesIntelligence is a comprehensive online platform that delivers the latest news, insights, and resources in the fields of life sciences, biotechnology, genetics/genomics, and pathology. It serves as a valuable hub for professionals, researchers, and industry experts to stay informed about cutting-edge advancements and emerging trends in these domains.

Nucleai is an AI-driven spatial biomarker analysis tool that leverages military intelligence-grade geospatial AI methods to analyze complex cellular interactions in a patient's biopsy. The platform offers a first-of-its-kind multimodal solution by ingesting images from various modalities and delivering actionable insights to optimize biomarker scoring, predict response to therapy, and revolutionize disease diagnosis and treatment.